WebJan 24, 2024 · About Finch Therapeutics Finch Therapeutics has a portfolio of microbiome assets including CP101, a late-stage, investigational, orally administered microbiome candidate with positive clinical data from a Phase 2 randomized, placebo-controlled trial and a Phase 2 open-label trial in recurrent C. difficile infection … WebCP101, an Investigational Oral Microbiome Therapeutic for the Prevention of Recurrent C. difficile Infection: A Combined Analysis of the PRISM3 (Randomized Placebo …

Finch Therapeutics Announces Removal of FDA Clinical Hold on …

WebAug 11, 2024 · Finch’s lead candidate, CP101, is in late-stage clinical development for the prevention of recurrent C. difficile infection and has received Breakthrough Therapy and Fast Track designations from the U.S. Food and Drug Administration. Finch is also developing FIN-211 for children with autism spectrum disorder and significant gastrointestinal ... WebJun 19, 2024 · SOMERVILLE, Mass.--(BUSINESS WIRE)-- Finch Therapeutics Group, Inc. (“Finch”), a clinical-stage microbiome drug development company, announced today positive topline results from PRISM3, its multi-center, randomized, double-blind, placebo-controlled Phase 2 trial of CP101, an investigational oral microbiome drug, for the … je raccourcir

Finch Therapeutics Announces Positive Topline Results from …

WebApr 29, 2024 · Finch’s lead candidate, CP101, is in late-stage clinical development for the prevention of recurrent C. difficile infection and has received Breakthrough Therapy and … WebSep 17, 2024 · Finch’s lead program, CP101, is an investigational microbiome drug with Fast Track and Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) for the prevention of ... WebNov 10, 2024 · About Finch Therapeutics. ... Finch announced that CP101 met its primary efficacy endpoint in PRISM3, the first of two pivotal trials to support the development of CP101 for the prevention of ... lamanix trading limited